Samuel Bernard

Dr. Samuel Bernard

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
SBSamuel Bernard
Samuel Bernard
TCTimothy W. Churchill
Timothy W. Churchill
MNMayooran Namasivayam
Mayooran Namasivayam
PBPhilippe B. Bertrand
Philippe B. Bertrand

1 December 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
PBPhilippe B Bertrand
Philippe B Bertrand
TCTimothy W Churchill
Timothy W Churchill
EYEvin Yucel
Evin Yucel
MNMayooran Namasivayam
Mayooran Namasivayam
SBSamuel Bernard
Samuel Bernard
JHJudy Hung
Judy Hung
The aim of this study was to define the natural history of patients with mitral annular calcification (MAC)-related mitral valve dysfunction and to assess the prognostic importance of mean transmitral pressure gradient (MG) and impact of concomitant mitral regurgitation (MR). The institutional echocardiography database was examined from 2001 to 2019 for all patients with MAC and MG ≥3 mmHg. A total of 5754 patients were stratified by MG in low (3–5 mmHg, n = 3927), mid (5–10 mmHg, n = 1476), and high (≥10 mmHg, n = 351) gradient. The mean age was 78 ± 11 years, and 67% were female. MR was none/trace in 32%, mild in 42%, moderate in 23%, and severe in 3%. Primary outcome was all-cause mortality, and outcome models were adjusted for age, sex, and MAC-related risk factors (hypertension, diabetes, coronary artery disease, chronic kidney disease). Survival at 1, 5, and 10 years was 77%, 42%, and 18% in the low-gradient group; 73%, 38%, and 17% in the mid-gradient group; and 67%, 25%, and 11% in the high-gradient group, respectively (log-rank P < 0.001 between groups). MG was independently associated with mortality (adjusted HR 1.064 per 1 mmHg increase, 95% CI 1.049–1.080). MR severity was associated with mortality at low gradients (P < 0.001) but not at higher gradients (P = 0.166 and 0.372 in the mid- and high-gradient groups, respectively). In MAC-related mitral valve dysfunction, mean transmitral gradient is associated with increased mortality after adjustment for age, sex, and MAC-related risk factors. Concomitant MR is associated with excess mortality in low-gradient ranges (3–5 mmHg) but gradually loses prognostic importance at higher gradients, indicating prognostic utility of transmitral gradient in MAC regardless of MR severity.

1 August 2020 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
TCTimothy W. Churchill
Timothy W. Churchill
PBPhilippe B. Bertrand
Philippe B. Bertrand
SBSamuel Bernard
Samuel Bernard
MNMayooran Namasivayam
Mayooran Namasivayam
JCJessica Churchill
Jessica Churchill
MPMichael H. Picard
Michael H. Picard

9 February 2022 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
EZEmily K. Zern
Emily K. Zern
DWDongyu Wang
Dongyu Wang
PRPaula Rambarat
Paula Rambarat
SBSamuel Bernard
Samuel Bernard
SPSamantha M. Paniagua
Samantha M. Paniagua
JHJennifer E. Ho
Jennifer E. Ho
Background: The pulmonary artery pulsatility index (PAPi), calculated from the ratio of the pulmonary artery pulse pressure to right atrial pressure, is a predictor of right ventricular failure after inferior myocardial infarction and left ventricular assist device implantation. Whether PAPi is associated with adverse outcomes across a heterogeneous population is unknown. Methods: We examined consecutive patients undergoing right heart catheterization between 2005 and 2016 in a hospital-based cohort. Multivariable Cox models were utilized to examine the association between PAPi and all-cause mortality, major adverse cardiac events, and heart failure hospitalizations. Results: We studied 8285 individuals (mean age 63 years, 39% women) with median PAPi across quartiles 1.7, 2.8, 4.2, and 8.7, who were followed over a mean follow-up of 6.7±3.3 years. Patients in the lowest PAPi quartile had a 60% greater risk of death compared with the highest quartile (multivariable-adjusted hazard ratio, 1.60 [95% CI, 1.36–1.88], P <0.001) and a higher risk of major adverse cardiac events and heart failure hospitalizations (hazard ratio, 1.80 [95% CI, 1.56–2.07], P <0.001 and hazard ratio, 2.08 [95% CI, 1.76–2.47], P <0.001, respectively). Of note, patients in quartiles 2 and 3 also had increased risk of cardiovascular events compared with quartile 4 (multivariable P <0.05 for all). Conclusions: Compared with the highest PAPi quartile, patients in PAPi quartiles 1 to 3 had a greater risk of all-cause mortality, major adverse cardiac events, and heart failure hospitalizations, with greatest risk observed in the lowest quartile. A low PAPi, even at values higher than previously reported, may serve an important role in identifying high-risk individuals across a broad spectrum of cardiovascular disease.

Verified
Journal Article
Open access
PDF file
SBSamuel Bernard
Samuel Bernard
RPRaymond Anthony Pashun
Raymond Anthony Pashun
BVBhavya Varma
Bhavya Varma
EYEugene Yuriditsky
Eugene Yuriditsky
Given the high morbidity and mortality associated with cardiopulmonary arrest, there have been multiple trials aimed at better monitoring and augmenting coronary, cerebral, and systemic perfusion. This article aims to elucidate these interventions, first by detailing the physiology of cardiopulmonary resuscitation and the available tools for managing cardiopulmonary arrest, followed by an in-depth examination of the newest advances in the monitoring and delivery of advanced cardiac life support.

1 August 2025 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
OLOrly Leiva
Orly Leiva
SSSteven Soo
Steven Soo
NSNathaniel R. Smilowitz
Nathaniel R. Smilowitz
HRHarmony Reynolds
Harmony Reynolds
BSBinita Shah
Binita Shah
GHGabriela Soriano Hobbs
Gabriela Soriano Hobbs
BACKGROUND: Myeloproliferative neoplasms (MPN) are a group of chronic leukemias that are associated with pulmonary hypertension (PH), which has been associated with increased risk adverse outcomes. The echocardiographic characterization of PH in MPN has not been reported, and the prognostic significance of PH among patients with MPN remains unclear. METHODS: This was a multicenter, retrospective cohort study of patients with MPN with ≥1 echocardiogram from 2010 to 2023. The echocardiographic probability of PH was determined according to the guidelines. The outcomes were hematologic progression and major adverse cardiovascular events. Exploratory analysis included outcomes among patients with right heart catheterization after the first echocardiogram, with PH defined as mean pulmonary artery pressure of >20 mm Hg. Multivariable Fine-Gray competing risk regression was used to estimate the subhazard ratio of hematologic progression and major adverse cardiovascular events. RESULTS: Five hundred fifty-five patients were included and 237 (42.7%) had an intermediate or high probability of PH on echocardiography. Over a median follow-up period of 51.2 months (interquartile range, 29.5–79.8), it was observed that echocardiographic probability of PH was associated with increased risk of hematologic progression (adjusted subhazard ratio, 1.92 [95% CI, 1.09–3.39]) and major adverse cardiovascular events (adjusted subhazard ratio, 1.66 [95% CI, 1.04–2.66]) but not all-cause death (adjusted hazard ratio, 1.51 [95% CI, 0.98–2.32]). Among patients with right heart catheterization (n=61), PH was present in 51 (83.6%) patients and was associated with a higher risk of hematologic progression (29.4% versus 0%; P =0.048). CONCLUSIONS: Among patients with MPN, echocardiographic probability of PH was associated with an increased risk of hematologic progression. Prospective studies are needed to assess the optimal use of echocardiography on MPN-specific prognostication.